Phaseline

Targets › NSCL1

NSCL1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Dec 2028.

Open in Phaseline: the race on NSCL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Xuanwu Hospital, BeijingEfavirenz
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
GDAP1, NSCL1Phase 3Creutzfeldt-Jakob DiseaseDec 2028

Conditions

Creutzfeldt-Jakob Disease (1)

Modalities

small molecule (1)

Companies

Xuanwu Hospital, Beijing (1)

Related targets

GDAP1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.